Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

Inclusion Criteria:

• Both genres.
• Age between 18 and 75 years.
• Clinical diagnosis of toxic optic neuropathy (afferent pupillary defect, acquireddyschromatopsia, visual loss and bilateral prechiasmatic field defect).
• Exposure with a temporal relationship of less than two weeks to a known toxicant forthe function of the optic nerve.
• Up to 21 days from symptom onset.
• Informed consent signature.

Exclusion Criteria:

• History of previous optic neuropathy.
• History of additional ophthalmological or neurological pathology that has causedpermanent visual loss.
• History of previous treatment with intravenous methylprednisolone or some otherexperimental treatment since the onset of symptoms.
• Poorly controlled diabetes mellitus.
• Poorly controlled systemic arterial hypertension.
• Hemoglobin >16 mg/dL
• Patients with a history of thromboembolic event.
• Patients with a history of coronary heart disease, myocardial infarction or cerebralvascular event.
• Pregnancy or lactation.